Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-01-23T18:27:58.285Z Has data issue: false hasContentIssue false
  • English
  • Français

Serotonin Function and Gender Effects in Migraine Production and OCD

Published online by Cambridge University Press:  07 November 2014

Cheryl M. Wong  and
Eric Hollander
Get access Rights & Permissions [Opens in a new window]

Abstract

A high prevalence of comorbidity has been reported between migraines and psychiatric disorders. It has been proposed that migraine headaches are mediated by stimulation of serotonin (5-HT) receptors. Past studies have demonstrated that migraine-like headaches have been produced following administration of the partial 5-HT agonist m-chlorophenylpiperazine (m-CPP; believed to primarily affect the 5-HT2C receptor) in patients with migraines or eating disorders, especially bulimia, as well as in normal controls. We review the association between 5-HT dysfunction, as determined by response to m-CPP challenge, and migraines, looking specifically at the relationship between migraines and obsessive-compulsive disorder and gender effects.

Type
Feature Articles
Information
CNS Spectrums , Volume 2 , Issue 2: Migraine: Pathophysiology & Comorbidity: A Window into Psychiatry and Neurology , February 1997 , pp. 25 - 27
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Griffith, SG, Burnstock, G. Immunohistochemical demonstration of serotonin in nerves supplying human cerebral and mesenteric blood vessels. Lancet. 1983;iii:561–562.CrossRefGoogle Scholar
2. Fozard, JR, Gray, JA. 5-HT1C receptor activation: a key step in the initiation of migraine? Trends in Pharmacol Sci. 1989;10:307–310.CrossRefGoogle Scholar
3. Brown, AM, Patch, TL, Kaumann, AJ. The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus. Br J Pharmacol. 1991;104:45–48.CrossRefGoogle Scholar
4. Curzon, G, Barrie, M, Wilkinson, IP. Relationships between headache and amine changes after administration of reserpine to migrainous patients. J Neural Neurosurg Psychiatry. 1969;32:555–561.CrossRefGoogle ScholarPubMed
5. Peroutka, SJ, Sleight, AJ, McCarthy, BG, Pierce, PA, Schmidt, AW, Hekmatpanah, CR. The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry. 1989;1:253–262.Google ScholarPubMed
6. Sicuteri, F. 5-Hydroxytryptophan in the prophylaxis of migraine. Pharmacol Res Communications. 1972;4:213–218.CrossRefGoogle Scholar
7. Catarci, T, Clifford, RF. Migraine and heredity. Pathol Biol Paris. 1992;40:284–286.Google ScholarPubMed
8. Brewerton, TD, Murphy, DL, Mueller, EA, Jimmerson, DC. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther. 1988;43:605–609.CrossRefGoogle Scholar
9. Brewerton, TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology. 1995;20:561–590.CrossRefGoogle Scholar
10. Kaye, WH, Gwirtsman, HE, Brewerton, TD, George, DT, Wurtsman, RJ. Bingeing behavior and plasma amino acids: a possible involvement of brain serotonin in bulimia nervosa. Psychiatry Res. 1987;23:31–43.CrossRefGoogle Scholar
11. Brewerton, TD, Mueller, EA, Lesem, MD, et al. , Neuroendocrine responses to m-CPP and L-Tryptophan in Bulimia. Arch Gen Psychiatry. 1992;49:852–861.CrossRefGoogle ScholarPubMed
12. Brewerton, TD, Murphy, DL, Lesem, MD, Brandt, HA, Jimerson, DC. Headache responses following m-CPP in bulimics and controls. Headache. 1992;32:217–222.CrossRefGoogle ScholarPubMed
13. Brewerton, TD, George, MS. Is migraine related to the eating disorders? Int J Eating Disorders. 1993;14:75–79.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
14. Gordon, ML, Lipton, RB, Brown, SL, et al. , Headache and cortisol responses to m-CPP are highly correlated. Cephalagia. 1993;13:400–405.CrossRefGoogle ScholarPubMed
15. Zohar, J, Mueller, EA, Insel, TR, Zohar-Kadouch, RC, Murphy, DL. Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:946–951.CrossRefGoogle ScholarPubMed
16. Charney, DS, Goodman, WK, Price, LH, Woods, SW, Rasmussen, SA, Heninger, GR. Serotonin function in obsessive-compulsive disorder. Arch Gen Psychiatry. 1988;45:177–185.CrossRefGoogle ScholarPubMed
17. Hollander, E, DeCaria, CM, Nitescu, A, et al. , Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992;49:21–28.CrossRefGoogle ScholarPubMed
18. Wong, CM, DeCaria, CM, Hollander, E. Amesergide pretreament of m-CPP response in normal controls. Biol Psychiatry. 1997;(Under submission)Google Scholar
19. Coccarro, EF, Kavoussi, RJ, Oakes, M, Cooper, TB, Hauger, R. 5-HT2a/2c receptor blockade by amesergide may attenuate prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 1996;126:24–30.CrossRefGoogle Scholar
20. Russell, MB, Rasmussen, BK, Thorvaldsen, P, Olesen, J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612–618.CrossRefGoogle ScholarPubMed
21. Kahn, RS, Wetzler, S, Asnis, GM, et al. , Effects of m-CPP in normal subjects: a dose-response study. Psychopharmacology. 1990;100:339–344.CrossRefGoogle ScholarPubMed
22. Wong, CM, Hollander, E. Headache response to m-CPP in OCD and normal controls. Biol Psychiatry. 1996;40:544–546.CrossRefGoogle Scholar
23. Carlsson, M, Sevensson, K, Eriksson, E, et al. , Rat brain serotonin biochemical and functional evidence for a sex difference. J Neural Transmission. 1985;63:297–313.CrossRefGoogle ScholarPubMed
24. Uphouse, L, Salamanca, S, Caldarola-Pastuska, M. Gender and estrous cycle differences in the response to the 5-HT agonist 8-OH-DPAT. Pharmacol Biochem Behav. 1991;40:901–906.CrossRefGoogle Scholar
25. Ciik, NE. Prolactin: normal synthesis, regulation and actions. In DeGroot, LJ, Rubenstein, AH, Steinberger, E, eds. Endocrinology. 2nd ed. Philadelphia, PA: WB Saunders Co; 1989;1:384–407.Google Scholar
26. Goodman, HM. Basic Medical Endocrinology. New York, NY: Raven Press; 1988.Google Scholar
27. Maurer, R. Relationship between estradiol ergocryptine, and thyroid hormone: effects on prolactin synthesis and prolactin mRNA levels. Endocrinology. 1982;110:1515–1520.CrossRefGoogle Scholar
28. Cramer, O, Parker, C, Porter, J. Estrogen inhibition of dopamine release into hypophyseal portal blood. Endocrinology. 1979;104:419–422.CrossRefGoogle Scholar
29. Wong, CM, DeCaria, CM, Hollander, E. 5-HT/Gender predictors of SRI treatment outcome in OCD. ACNP Annual Meeting, Puerto Rico, December 1996. Abstract.Google Scholar